BioNTech's recent pipeline setback is a real cause of concern. But investors shouldn't panic.

Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's ...

Investors buying this biotech stock now will get its pipeline essentially for free.

For BioNTech, the readout offers tangible evidence that its pivot toward oncology is producing results rather than just promises. The company has spent years signaling its intent to move beyond ...

A coveted Presidential Symposium slot at Europe's top oncology congress just sent Moderna shares flying 9%, but the actual ...

Pfizer Canada ULC and BioNTech SE today announced that Health Canada has authorized the XFG variant-adapted COMIRNATY® for active immunization of individuals aged 6 months and older against COVID-19.

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

The scientific case rests on updated results from PRESERVE-003, a Phase 3 trial run with partner OncoC4. The study tested Gotistobart as a monotherapy against the chemotherapy agent Docetaxel in ...

Wondering how Pfizer and partner BioNTech developed a COVID-19 vaccine in record time without compromising safety? Dr Bill ...

BioNTech SE (NASDAQ:BNTX) is ending a mid-stage study of its personalized mRNA cancer vaccine, autogene cevumeran, after an independent monitoring committee concluded that continuing the trial was ...

COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closely match contemporary circulating ...

Trial stopped after review deems it unlikely to succeed Separate study for pancreatic cancer patients to continue Setback comes after Merck-Moderna's recent success in melanoma patients U.S.-listed ...